FDA Approves Pfizer’s Biosimilar, RUXIENCE (rituximab-pvvr), for Certain Cancers and Autoimmune Conditions Read more
Merck and Eisai Receive Third Breakthrough Therapy Designation from FDA for KEYTRUDA (pembrolizumab) plus LENVIMA (lenvatinib) Combination Treatment Read more
Johnson & Johnson Establishes International Consortium to Advance Pioneering Science in the Fight to End Tuberculosis Read more
ContraVir Pharmaceuticals Announces Name Change to Hepion Pharmaceuticals, Inc.; Trading Symbol Change to “HEPA” Read more
Avalon GloboCare and GE Healthcare Announce Strategic Partnership to Accelerate Standardized Automation and Bio-production for Cellular Medicines Read more
Baxter Announces FDA Approval of Myxredlin, the First and Only Ready-To-Use Insulin for IV Infusion Read more
Sandoz announces first patient enrolled in clinical study for proposed biosimilar denosumab in osteoporosis Read more
ACADIA Pharmaceuticals Announces Top-line Results from Phase 3 ENHANCE Trial of Pimavanserin Read more
Vertex Submits New Drug Application to the FDA for Triple Combination Regimen of VX-445 (Elexacaftor), Tezacaftor and Ivacaftor in Cystic Fibrosis Read more